SYNOPSIS

Report on

Smart Multi-Modal Detection of Parkinson's Disease

By

SYED ZAID ASHRAF (202410116100215)
ZEESHAN MALIK (202410116100255)
SUHEL SAIFI (202410116100213)
VISHAL SHAKYA (202410116100250)

Session:2025-2026 (III Semester)

Under the supervision of
Dr. Neelam Rawat
Ms. Anita Yada

KIET Group of Institutions, Delhi-NCR, Ghaziabad

DEPARTMENT OF COMPUTER APPLICATIONS
KIET GROUP OF INSTITUTIONS, DELHI-NCR,
GHAZIABAD-201206

ABSTRACT

Parkinson's Disease (PD) is a progressive neurodegenerative disorder traditionally diagnosed through clinical evaluation of motor symptoms such as tremor, bradykinesia, rigidity, and postural instability. However, by the time these symptoms become apparent, significant neural damage has already occurred. This delay underscores the critical need for early, accurate, and objective detection methods.

This research presents a smart, multi-modal artificial intelligence (AI) system designed to identify Parkinson's Disease in its pre-motor phase by leveraging digital biomarkers from diverse data sources. The system integrates:

- Wearable sensors (accelerometers, gyroscopes) to continuously monitor gait, tremor, finger tapping speed, and balance.
- Smartphone applications that administer dexterity tests, record voice samples, and capture kinematic handwriting data via spiral drawing tasks.
- Medical imaging enhancements, where AI analyzes DaTscan and MRI data to quantify dopamine deficits and subtle brain changes.
- Non-motor biomarkers including sleep analysis (e.g., detection of REM sleep behavior disorder), olfactory loss tests, and heart rate variability monitoring.

Data acquired from these modalities undergo rigorous preprocessing and feature extraction. Machine learning models—including classical algorithms like Support Vector Machines (SVM) and Random Forest, as well as deep learning approaches such as Convolutional and Recurrent Neural Networks (CNNs/RNNs)—are employed to analyze the integrated dataset. These models are trained to distinguish between PD-afflicted and healthy individuals with high accuracy, and support longitudinal tracking to monitor disease progression and treatment response.

Key benefits of this approach include:

- Early detection, often years before overt motor symptoms emerge.
- Objective and quantifiable assessment, reducing reliance on subjective clinical ratings.
- Remote and continuous monitoring, enabling real-world, high-frequency data collection outside clinical settings.
- Democratized access to advanced diagnostics through consumer-grade devices like smartphones and wearables.

TABLE OF CONTENTS

INTRODUCTION

Parkinson's Disease (PD) is a progressive neurodegenerative disorder that significantly impairs motor and non-motor functions, affecting millions of individuals worldwide. Early detection is critical for effective intervention, yet traditional diagnostic methods rely heavily on clinical observations of symptoms such as tremor, bradykinesia, and rigidity, which often manifest only after substantial neuronal damage has occurred. The complexity and variability of PD symptoms, combined with the lack of accessible and objective diagnostic tools, underscore the urgent need for intelligent systems capable of identifying the disease in its earliest stages.

Advances in Artificial Intelligence (AI) and Machine Learning (ML) have transformed healthcare by enabling data-driven, personalized solutions. From medical imaging to wearable technology, AI-powered systems are increasingly used to analyze complex biomedical data, detect subtle patterns, and support clinical decision-making. Applying these technologies to Parkinson's research offers a promising pathway to revolutionize diagnostics through smart, multi-modal data integration.

The proposed project, **Smart Multi-Modal Detection of Parkinson's Disease,** aims to develop an AI-based platform that combines data from wearable sensors, voice recordings, handwriting tasks, and medical imaging to detect early signs of PD. The system utilizes a curated dataset of kinematic, acoustic, and physiological biomarkers extracted from these diverse modalities. By employing machine learning models—including classical algorithms and deep learning architectures—it learns to distinguish between PD-afflicted and healthy individuals with high accuracy.

A user-friendly web and mobile interface allows individuals to perform simple tasks such as voice recordings, spiral drawing, and gait tests using everyday devices like smartphones and wearables. The system processes this multi-modal input in real time, generating comprehensive reports indicating PD risk levels and progression trends. This interactive, accessible design ensures the technology can be used in both clinical and remote settings, enabling continuous monitoring and early intervention.

Background and Motivation

Parkinson's Disease is the second most common neurodegenerative disorder globally, with incidence rates rising due to aging populations. Early detection is crucial for initiating neuroprotective treatments, managing symptoms, and improving quality of life. However, existing diagnostic approaches are often subjective, reliant on specialist expertise, and inaccessible in remote or underserved regions. Non-motor symptoms such as sleep disorders, loss of smell, and autonomic dysfunction—which can precede motor symptoms by years—are frequently overlooked in conventional assessments.

The motivation for this project stems from the pressing need to make PD diagnostics more accurate, equitable, and patient-centric. By integrating AI with multi-modal data acquisition, it aims to bridge the gap between clinical practice and technological innovation, empowering both patients and clinicians with data-driven insights.

Problem Statement

The complexity and variability of Parkinson's symptoms make early and accurate diagnosis challenging using traditional methods. Current tools are often expensive, invasive, or dependent on highly specialized settings, limiting their scalability and accessibility. There is a significant lack of intelligent, integrated systems that can combine heterogeneous biomarkers—such as vocal changes, handwriting kinematics, and gait abnormalities—into a unified, automated diagnostic framework.

It addresses this gap by offering a lightweight, AI-powered platform that leverages multi-modal data and machine learning to deliver personalized, explainable, and early diagnostic support.

Scope of the Project

The scope of NeuroTrack includes:

1. Developing a multi-modal AI system that integrates data from sensors, voice recordings, digitized handwriting, and medical imaging.
2. Implementing feature extraction and machine learning models (e.g., CNNs, SVMs, Random Forests) to analyze biomarkers and detect patterns indicative of PD.
3. Designing an intuitive user interface for seamless interaction and real-time feedback.
4. Providing longitudinal tracking capabilities to monitor symptom progression and treatment response.
5. Establishing a scalable and modular architecture capable of incorporating new data sources (e.g., sleep data, olfaction tests) in the future.
6. Ensuring the system is accessible, privacy-aware, and designed for use in diverse and low-resource settings.

Significance of the Project

The significance of NeuroTrack lies in its potential to transform Parkinson's diagnostics from reactive to proactive. For patients, it offers a non-invasive, continuous, and reliable means of monitoring their health, facilitating earlier intervention and personalized care plans. For clinicians, it serves as a decision-support tool that enhances diagnostic accuracy and reduces subjectivity. For the global healthcare community, it demonstrates how AI can democratize access to advanced diagnostics, support preventive neurology, and reduce the burden on traditional healthcare systems.

By aligning with sustainable and scalable digital health solutions, NeuroTrack not only aims to improve outcomes for individuals at risk of or living with Parkinson’s but also contributes to the broader movement toward AI-enhanced, personalized, and accessible healthcare worldwide.

LITERATURE REVIEW

- Multi-Modal Data Integration in PD Diagnostics: Research demonstrates that combining diverse biomarkers (e.g., voice, gait, handwriting) significantly enhances early detection accuracy (Tsanas et al., 2016).
- AI/ML in Parkinson’s Research: Machine learning models (e.g., SVM, Random Forests, CNNs) are widely adopted to analyze sensor-derived data and classify PD with high precision (Esteva et al., 2019).
- Wearable Sensor Technology: Studies highlight the role of accelerometers and gyroscopes in continuous monitoring of motor symptoms (Maetzler et al., 2013).
- Voice and Acoustic Analysis: Vocal features (jitter, shimmer, HNR) serve as effective digital biomarkers for pre-symptomatic PD detection (Sakar et al., 2013).
- Digitized Handwriting Kinematics: Spiral drawing tests quantify micrographia and hesitation, providing sensitive indicators of early PD (Drotár et al., 2016).
- Challenges: Data privacy, algorithmic bias, clinical validation, and integration of heterogeneous data sources remain critical hurdles (Hirschauer et al., 2015).

RESEARCH OBJECTIVE

The main objectives of the project are:

1. To design and implement an AI-based multi-modal system for early detection and monitoring of Parkinson's Disease.
2. To integrate and analyze heterogeneous data sources (e.g., voice, gait, handwriting, sensor data) using machine learning and deep learning models.
3. To develop an interactive and accessible web/mobile interface for real-time user interaction and clinical support.
4. To provide a decision-support tool for clinicians and patients enabling proactive and personalized Parkinson's management.
5. To promote early intervention and improve quality of life by reducing diagnostic delays and enabling continuous health tracking.

HARDWARE AND SOFTWARE REQUIREMENTS

4.1. Hardware Requirements:

- Development Environment: Laptop/Desktop with 8GB RAM, i5 processor (or above)
- Data Acquisition Devices: Wearable sensors (e.g., accelerometers, gyroscopes), smartphones with microphones and touchscreens, clinical-grade motion capture systems (optional for validation)
- Server Requirement: Cloud hosting with high computational capacity (e.g., AWS, Google Cloud, or Azure) for model training and real-time analysis
- Client Requirement: Standard web browsers (Chrome, Firefox, Edge) or mobile devices (iOS/Android) for user interface interaction

4.2. Software Requirements:

- Programming Language: Python (pandas, numpy, scikit-learn, TensorFlow/PyTorch, Librosa for audio processing, OpenCV for image analysis)
- Frontend: Streamlit for web interface or React Native for mobile applications
- ML/DL Models: SVM, Random Forest, CNN, RNN, and sensor data processing libraries (e.g., SciPy for signal processing)
- Data Sources: Multi-modal datasets (voice recordings, gait sensor data, digitized handwriting samples, medical imaging where available)
- Deployment: Docker containers, cloud platforms (AWS/Azure/Google Cloud), or on-premise servers for clinical integration
- Version Control: GitHub/GitLab for collaborative development
- Privacy/Security: Encryption protocols (e.g., HIPAA compliance) for handling sensitive health data

PROJECT FLOW

5.1. Problem Identification & Scope

- Problem: Traditional methods for Parkinson's Disease (PD) detection are subjective, late-stage, and inaccessible in remote areas.
- Scope: Develop an AI-powered multi-modal system integrating sensor data, voice analysis, and handwriting kinematics for early PD detection and continuous monitoring.

5.2. Requirement Analysis

- Functional: Multi-modal data processing (gait, voice, handwriting), AI-driven diagnosis, real-time feedback, and longitudinal tracking.
- Non-Functional: Scalability, interoperability with wearables/smartphones, data privacy (HIPAA/GDPR compliance), and clinical-grade accuracy.

5.3. Data Collection & Integration

- Data Sources:
    - Wearable sensors (accelerometer/gyroscope data for gait and tremor analysis).
    - Voice recordings (acoustic features: jitter, shimmer, HNR).
    - Digitized handwriting tasks (spiral drawings for kinematic analysis).
    - Optional: Medical imaging (DaTscan/MRI) and sleep/smell test data.
- Preprocessing: Noise filtering, feature extraction, and normalization of heterogeneous data.

5.4. Prototype Development

- Phase 1: Data preprocessing pipeline for multi-modal inputs (sensor signals, audio, handwriting kinematics).
- Phase 2: Machine learning model development (e.g., SVM/Random Forest for classification, CNNs for raw data analysis).
- Phase 3: Integration of cloud-based AI engine with web/mobile interface (Streamlit or React Native).
- Phase 4: Implementation of longitudinal tracking and clinician dashboard features.

5.5. Testing & Evaluation

- Functional Testing: Model accuracy (precision, recall, F1-score), biomarker sensitivity/specificity.
- Usability Testing: Interface intuitiveness for patients/clinicians, accessibility across devices.
- Performance Testing: Latency in real-time data processing, scalability for large datasets.
- Clinical Validation: Correlation with gold-standard diagnoses (e.g., UPDRS scores, neurologist assessments).

5.6. Outcome & Refinement

- Deliverables:

    - A validated multi-modal PD detection system with AI-driven insights.
    - Secure web/mobile platform for users and clinicians.
- Refinement:
    - Incorporate clinician feedback for improved diagnostic relevance.
    - Expand biomarker diversity (e.g., sleep, olfaction data) and adapt models for global populations.
    - Pursue regulatory approvals (FDA/CE marking) for clinical deployment.

RESEARCH OUTCOME

The NeuroTrack project delivers significant outcomes at both technical and practical levels, demonstrating how multi-modal AI can transform early detection and management of Parkinson's Disease (PD). The system integrates diverse biomarkers and machine learning to provide accurate, accessible, and proactive diagnostic support. The detailed outcomes are as follows:

Functional Multi-Modal PD Detection System

- The project successfully develops a fully functional AI-powered platform for early PD detection and continuous monitoring.
- Users and clinicians can input multi-modal data (e.g., voice recordings, gait sensor readings, handwriting samples) and receive real-time risk assessments and progression reports.
- The system provides actionable insights, including biomarker trends and personalized recommendations for clinical follow-up.

Integration of AI and Multi-Modal Data Analysis

- The system showcases the application of machine learning (e.g., SVM, Random Forests, CNNs) and signal processing techniques to analyze heterogeneous data sources.
- Unlike traditional diagnostic methods, the platform combines motor and non-motor biomarkers (e.g., vocal features, kinematic handwriting data, gait patterns) for comprehensive assessment.
- This outcome highlights the adaptability of AI in clinical neuroscience and its potential to address complex neurodegenerative disorders.

Improved Diagnostic Accuracy and Early Intervention

- NeuroTrack addresses the critical challenge of late-stage PD diagnosis by identifying pre-symptomatic signs through digital biomarkers.
- By enabling early detection, the system facilitates timely intervention, personalized treatment plans, and improved long-term patient outcomes.
- This makes the project a pivotal tool in preventive neurology, reducing healthcare costs and enhancing quality of life for at-risk individuals.

User-Friendly and Clinically Adaptable Interface

- The system employs an intuitive web/mobile interface (e.g., Streamlit or React Native) for seamless interaction by patients and clinicians.
- Even non-technical users can easily perform tasks (e.g., voice recordings, spiral drawings) and interpret results, ensuring accessibility across diverse settings.
- The design prioritizes usability in both clinical and remote environments, bridging gaps in healthcare accessibility.

Contribution to Neurology and Digital Health

- NeuroTrack demonstrates how AI can be integrated into clinical workflows to augment diagnostic precision and efficiency.
- The tool has potential applications in telemedicine, clinical trials, and global health initiatives, particularly in underserved regions with limited neurological expertise.

- This outcome positions the project as a scalable solution for real-world adoption in healthcare systems worldwide.

Research and Academic Value

- The project provides a robust framework for multi-modal data fusion and AI-driven biomarker analysis in neurodegenerative disease research.
- It contributes to academic discourse by addressing challenges such as data heterogeneity, model interpretability, and clinical validation.
- Future researchers can extend NeuroTrack with advanced features (e.g., federated learning, real-time sensor integration, and deep learning architectures).

Patient-Centric and Societal Outcomes

- From a patient perspective, NeuroTrack empowers individuals to proactively monitor their health and engage in personalized care plans.
- The system reduces diagnostic delays, minimizes unnecessary clinical visits, and alleviates burdens on healthcare infrastructure.
- Societally, it promotes equitable access to advanced diagnostics and supports broader public health goals related to aging populations.

Future Directions and Scalability

- While the current project focuses on PD, the framework can be adapted for other neurodegenerative disorders (e.g., Alzheimer’s, Essential Tremor).
- Future developments may include integration with electronic health records (EHRs), IoT-based home monitoring systems, and regulatory approvals (e.g., FDA clearance).
- These directions ensure NeuroTrack remains at the forefront of digital neurology innovation, driving sustainable impact in global healthcare.

PROPOSED TIME DURATION

Task	Duration
Requirement Analysis	1 Week
Multi-Modal Data Collection	2 Weeks
Data Preprocessing & Feature Extraction	2 Weeks
Model Development (ML/DL)	3 Weeks
Web/Mobile Interface Development	2 Weeks
System Integration & Testing	2 Weeks
Clinical Validation & Refinement	3 Weeks
Deployment & Documentation	2 Weeks

REFERENCES / BIBLIOGRAPHY

1. Esteva, A., Kuprel, B., Novoa, R. A., et al. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118.
2. Tsanas, A., Little, M. A., McSharry, P. E., et al. (2012). Accurate telemonitoring of Parkinson’s disease progression by noninvasive speech tests. IEEE Transactions on Biomedical Engineering, 57(4), 884–893.
3. Maetzler, W., Domingos, J., Srulijes, K., et al. (2013). Quantitative wearable sensors for objective assessment of Parkinson’s disease. Movement Disorders, 28(12), 1628–1637.
4. Drotár, P., Mekyska, J., Rektorová, I., et al. (2016). Evaluation of handwriting kinematics and pressure for differential diagnosis of Parkinson’s disease. Artificial Intelligence in Medicine, 67, 39–46.
5. Hirschauer, T. J., Adeli, H., & Buford, J. A. (2015). Computer-aided diagnosis of Parkinson’s disease using enhanced probabilistic neural network. Journal of Medical Systems, 39(11), 1–12.
6. Sakar, B. E., Isenkul, M. E., Sakar, C. O., et al. (2013). Collection and analysis of a Parkinson speech dataset with multiple types of sound recordings. IEEE Journal of Biomedical and Health Informatics, 17(4), 828–834.
7. Postuma, R. B., Berg, D., Stern, M., et al. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders, 30(12), 1591–1601.
8. Goetz, C. G., Tilley, B. C., Shaftman, S. R., et al. (2008). Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). Movement Disorders, 23(15), 2129–2170.
9. Rizzo, G., Copetti, M., Arcuti, S., et al. (2016). Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology, 86(6), 566–576.
10. Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284–2303.
11. Lang, A. E., & Lozano, A. M. (1998). Parkinson’s disease. New England Journal of Medicine, 339(15), 1044–1053.
12. Deuschl, G., Antonini, A., Costa, J., et al. (2022). European Academy of Neurology/MDS-ES recommendations for the diagnosis of Parkinson’s disease. European Journal of Neurology, 29(4), 1141–1150.
13. Obeso, J. A., Stamelou, M., Goetz, C. G., et al. (2017). Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 32(9), 1264–1310.
14. Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006). Non-motor symptoms of Parkinson’s disease: Diagnosis and management. The Lancet Neurology, 5(3), 235–245.
15. WHO (2022). Global Status Report on the Public Health Response to Dementia. World Health Organization.